Characterization of Human Papillomavirus Antibodies in Individuals with Head and Neck Cancer

Overview

Journal Cancer Epidemiol

Publisher Elsevier

Specialties Oncology
Public Health

Date 2016 Mar 25

PMID 27010729

Citations 18

Authors

Krystle A Lang Kuhs

Michael Pawlita

Sandra P Gibson

Nicole C Schmitt

Sumita Trivedi

Athanassios Argiris

Aimee R Kreimer

Robert L Ferris

Tim Waterboer

Affiliations

Soon will be listed here.

Abstract

Background: Human papillomavirus type 16 (HPV16) E6 antibodies are a promising biomarker of oropharyngeal cancer (OPC); however, seropositivity among non-OPC cases is not well characterized.

Methods: Pre-treatment sera from 260 (38 OPC, 222 non-OPC) incident head and neck cancers diagnosed at the University of Pittsburgh between 2003 and 2006 were tested for HPV16 (L1,E1,E2,E4,E6,E7) and non-HPV16 E6 (HPV6,11,18,33) antibodies. Sensitivity and specificity of HPV16 E6 antibodies for HPV-driven tumors was evaluated among tumors with known HPV status (n=25).

Results: 63.2% of OPC versus 27.5% of non-OPC cases were HPV16 seropositive; HPV16 E6 seroprevalence was 60.5% and 6.3% respectively, odds ratio 22.8 (95% confidence interval [CI] 9.8-53.1). Sensitivity and specificity of HPV16 E6 antibodies for HPV-driven OPC was 100% [95% CI: 50-100%; n=6] and 100% [95% CI: 60-100%, n=4] compared to 0% (n=2) and 0% (n=13) for non-OPC cases.

Conclusions: HPV16 antibodies were significantly more common in OPC versus non-OPC cases, particularly HPV16 E6 antibodies.

Citing Articles

Detection of antibody subclasses IgA, IgM and IgG against HPV L1 in HPV-positive oropharyngeal squamous cell carcinoma patients: a pilot study.

Weiland T, Zgubic J, Brcic L, Thurnher D Eur Arch Otorhinolaryngol. 2024; 281(5):2637-2644.

PMID: 38441604 PMC: 11023979. DOI: 10.1007/s00405-024-08537-9.

The Tumor-Specific Immune Landscape in HPV+ Head and Neck Cancer.

Conarty J, Wieland A Viruses. 2023; 15(6).

PMID: 37376596 PMC: 10301020. DOI: 10.3390/v15061296.

Absolute Risk of Oropharyngeal Cancer After an HPV16-E6 Serology Test and Potential Implications for Screening: Results From the Human Papillomavirus Cancer Cohort Consortium.

Robbins H, Ferreiro-Iglesias A, Waterboer T, Brenner N, Nygard M, Bender N J Clin Oncol. 2022; 40(31):3613-3622.

PMID: 35700419 PMC: 9622695. DOI: 10.1200/JCO.21.01785.

Germline determinants of humoral immune response to HPV-16 protect against oropharyngeal cancer.

Ferreiro-Iglesias A, McKay J, Brenner N, Virani S, Lesseur C, Gaborieau V Nat Commun. 2021; 12(1):5945.

PMID: 34642315 PMC: 8511029. DOI: 10.1038/s41467-021-26151-9.

Sensitivity and Specificity of Human Papillomavirus (HPV) 16 Early Antigen Serology for HPV-Driven Oropharyngeal Cancer: A Systematic Literature Review and Meta-Analysis.

Hibbert J, Halec G, Baaken D, Waterboer T, Brenner N Cancers (Basel). 2021; 13(12).

PMID: 34208476 PMC: 8234521. DOI: 10.3390/cancers13123010.

References

Mendoza Lopez R, Levi J, Eluf-Neto J, Koifman R, Koifman S, Curado M . Human papillomavirus (HPV) 16 and the prognosis of head and neck cancer in a geographical region with a low prevalence of HPV infection. Cancer Causes Control. 2014; 25(4):461-71. DOI: 10.1007/s10552-014-0348-8. View

Argiris A, Heron D, Smith R, Kim S, Gibson M, Lai S . Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer. J Clin Oncol. 2010; 28(36):5294-300. PMC: 3018361. DOI: 10.1200/JCO.2010.30.6423. View

Anantharaman D, Gheit T, Waterboer T, Abedi-Ardekani B, Carreira C, McKay-Chopin S . Human papillomavirus infections and upper aero-digestive tract cancers: the ARCAGE study. J Natl Cancer Inst. 2013; 105(8):536-45. DOI: 10.1093/jnci/djt053. View

Gillison M, Alemany L, Snijders P, Chaturvedi A, Steinberg B, Schwartz S . Human papillomavirus and diseases of the upper airway: head and neck cancer and respiratory papillomatosis. Vaccine. 2012; 30 Suppl 5:F34-54. DOI: 10.1016/j.vaccine.2012.05.070. View

Ioka A, Tsukuma H, Ajiki W, Oshima A . Trends in head and neck cancer incidence in Japan during 1965-1999. Jpn J Clin Oncol. 2005; 35(1):45-7. DOI: 10.1093/jjco/hyi004. View

Chaturvedi A, Engels E, Pfeiffer R, Hernandez B, Xiao W, Kim E . Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011; 29(32):4294-301. PMC: 3221528. DOI: 10.1200/JCO.2011.36.4596. View

Smith E, Rubenstein L, Haugen T, Pawlita M, Turek L . Complex etiology underlies risk and survival in head and neck cancer human papillomavirus, tobacco, and alcohol: a case for multifactor disease. J Oncol. 2012; 2012:571862. PMC: 3270416. DOI: 10.1155/2012/571862. View

Waterboer T, Sehr P, Michael K, Franceschi S, Nieland J, Joos T . Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins. Clin Chem. 2005; 51(10):1845-53. DOI: 10.1373/clinchem.2005.052381. View

Singhi A, Westra W . Comparison of human papillomavirus in situ hybridization and p16 immunohistochemistry in the detection of human papillomavirus-associated head and neck cancer based on a prospective clinical experience. Cancer. 2010; 116(9):2166-73. DOI: 10.1002/cncr.25033. View

10.

Hocking J, Stein A, Conway E, Regan D, Grulich A, Law M . Head and neck cancer in Australia between 1982 and 2005 show increasing incidence of potentially HPV-associated oropharyngeal cancers. Br J Cancer. 2011; 104(5):886-91. PMC: 3048203. DOI: 10.1038/sj.bjc.6606091. View

11.

Blomberg M, Nielsen A, Munk C, Kjaer S . Trends in head and neck cancer incidence in Denmark, 1978-2007: focus on human papillomavirus associated sites. Int J Cancer. 2010; 129(3):733-41. DOI: 10.1002/ijc.25699. View

12.

Braakhuis B, Visser O, Leemans C . Oral and oropharyngeal cancer in The Netherlands between 1989 and 2006: Increasing incidence, but not in young adults. Oral Oncol. 2009; 45(9):e85-9. DOI: 10.1016/j.oraloncology.2009.03.010. View

13.

Clifford G, Shin H, Oh J, Waterboer T, Ju Y, Vaccarella S . Serologic response to oncogenic human papillomavirus types in male and female university students in Busan, South Korea. Cancer Epidemiol Biomarkers Prev. 2007; 16(9):1874-9. DOI: 10.1158/1055-9965.EPI-07-0349. View

14.

Chaturvedi A, Engels E, Anderson W, Gillison M . Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol. 2008; 26(4):612-9. DOI: 10.1200/JCO.2007.14.1713. View

15.

Ndiaye C, Mena M, Alemany L, Arbyn M, Castellsague X, Laporte L . HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta-analysis. Lancet Oncol. 2014; 15(12):1319-31. DOI: 10.1016/S1470-2045(14)70471-1. View

16.

Waterboer T, Sehr P, Pawlita M . Suppression of non-specific binding in serological Luminex assays. J Immunol Methods. 2006; 309(1-2):200-4. DOI: 10.1016/j.jim.2005.11.008. View

17.

Sitas F, Egger S, Urban M, Taylor P, Abnet C, Boffetta P . InterSCOPE study: Associations between esophageal squamous cell carcinoma and human papillomavirus serological markers. J Natl Cancer Inst. 2012; 104(2):147-58. PMC: 3260131. DOI: 10.1093/jnci/djr499. View

18.

Reddy V, Cundall-Curry D, Bridger M . Trends in the incidence rates of tonsil and base of tongue cancer in England, 1985-2006. Ann R Coll Surg Engl. 2010; 92(8):655-9. PMC: 3229372. DOI: 10.1308/003588410X12699663904871. View

19.

Combes J, Franceschi S . Role of human papillomavirus in non-oropharyngeal head and neck cancers. Oral Oncol. 2013; 50(5):370-9. DOI: 10.1016/j.oraloncology.2013.11.004. View

20.

Kreimer A, Johansson M, Waterboer T, Kaaks R, Chang-Claude J, Drogen D . Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. J Clin Oncol. 2013; 31(21):2708-15. PMC: 3709056. DOI: 10.1200/JCO.2012.47.2738. View